Zerumbone-Loaded Nanostructured Lipid Carrier Induces Apoptosis of Canine Mammary Adenocarcinoma Cells

Table 2

LC₅₀, TGI, and GI₅₀ values for canine mammary gland tumor (CMT) adenocarcinoma cells treated with ZER-NLC, ZER, DOXO.

Concentration (μM)		Treatments
	Time (h)	ZER-NLC	ZER	DOXO
LC50	24	84.70 ± 8.68	128.68 ± 5.47	95.99 ± 10.54
	48	68.61 ± 10.10	84.86 ± 14.30	19.62 ± 5.83
	72	84.54 ± 10.44	94.63 ± 10.80	5.89 ± 0.05
TGI	24	20.47 ± 10.52	46.22 ± 10.12	24.91 ± 10.88
	48	23.52 ± 6.87	34.39 ± 5.87	4.51 ± 0.08
	72	27.29 ± 4.87	32.28 ± 1.29	3.93 ± 0.03
GI50	24	4.12 ± 0.97	18.49 ± 3.63	4.39 ± 0.77
	48	4.32 ± 0.71	11.44 ± 2.48	2.25 ± 0.04
	72	8.63 ± 1.16	11.36 ± 0.42	1.96 ± 0.02

Data are mean ± SD (n=3), analyzed using one-way ANOVA and post hoc Tukeytest.
DOXO: doxorubicin; GI₅₀: growth inhibition concentration 50; LC50: lethal concentration 50; TGI: total growth inhibition concentration; ZER: zerumbone; ZER-NLC: zerumbone-loaded nanostructured lipid carrier.